Androgens and prostate cancer: Biology, pathology and hormonal therapy

European Journal of Cancer Part A

Volumn 33, Issue 4, 1997, Pages 545-554

  Galbraith, S M ^a   Duchesne, G M ^a  

^a MIDDLESEX HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANDROGEN; ANDROGEN RECEPTOR; ANTIANDROGEN; BICALUTAMIDE; CYPROTERONE; DIETHYLSTILBESTROL; FINASTERIDE; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; HYDROCORTISONE; KETOCONAZOLE; NILUTAMIDE; PROTEIN BCL 2; PROTEIN P53; SOMATOSTATIN DERIVATIVE; STEROID 5ALPHA REDUCTASE INHIBITOR; SURAMIN;

ADRENAL INSUFFICIENCY; ALCOHOL TOLERANCE; ANDROGEN SYNTHESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; EDEMA; FATIGUE; GASTROINTESTINAL TOXICITY; GYNECOMASTIA; HOT FLUSH; HUMAN; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; IMPOTENCE; KIDNEY DISEASE; LIVER TOXICITY; MALE; NEUROPATHY; NUTRITIONAL INTOLERANCE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CARCINOMA; RANDOMIZED CONTROLLED TRIAL; RASH; REVIEW; THROMBOEMBOLISM;

EID: 0030995035     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00444-3     Document Type: Article

References (78)

1. Cunha GR, Donjacour AA, Cooke PJ, et al. The endocrinology and developmental biology of the prostate. Endocr Rev 1987, 8, 338-362.
2. McConnell JD. Physiologic basis of endocrine therapy for prostatic cancer. Urol Clin N Am 1991, 18, 1-12.
3. Harper ME, Pike A, Peeling WB, Griffith D. Steroids of adrenal origin metabolised by human prostatic tissue in vivo and in vitro. J Endocrinol 1974, 60, 117-125.
4. Geller J, Albert JD, Nachtsheim DA, Loza D. Comparison of prostatic cancer tissue DHT levels at the time of relapse following orchiectomy or oestrogen therapy. J Urol 1984, 132, 693-696.
5. Smith C, Assimos D, Lee C, Grayhack JT. Metabolic action of prolactin on the prostate: independent of androgen action. Prostate 1985, 6, 49.
6. Sibley PEC, Harper ME, Pike A, Peeling WB, Griffith D. Growth hormone and prostatic tumours: localisation using a monoclonal human growth hormone antibody. J Endocrinol 1984, 103, 311-315.
7. Maddy SQ, Chisholm GD, Hawkins RA, Habib HK. Localisation of epidermal growth factor receptors in the human prostate by biochemical and immunocytochemical methods. J Endocrinol 1987, 113, 147-153.
8. Wilson EM, Smith EP. Growth factors in the prostate. Prog Clin Biol Res 1987, 239, 205-233.
9. Carruba G, Leake RE, Rinaldi F, et al. Steroid growth factor interactions in human prostate cancer cells. Steroids 1994, 59, 412-420.
10. Conover CA, Perry JE, Tindall DJ. Endogenous cathepsin-D mediated hydrolysis of IGF-binding proteins in cultured human prostatic carcinoma cells. J Clin Endocrinol Metab 1995, 80, 987-993.
11. di-Sant'Agnese PA. Neuroendocrine differentiation in human prostatic carcinoma. Hum Pathol 1992, 23, 287-296.
12. Brinkman AO, Faber PW, van Rooj HCJ, et al. The human androgen receptor; domain structure, genomic organisation and regulation of expression. J Steroid Biochem 1989, 34, 307-310.
13. Furuya Y, Lin XS, Walsh JC, Nelson WG, Isaacs JT. Androgen ablation induced programmed death of prostatic glandular cells does not involve recruitment into a defective cell cycle or p53 induction. Endocrinology 1995, 136, 1898-1906.
14. Kypriana N, English HF, Isaacs JT. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res 1990, 50, 3748.
15. Sinha BK, Yamazaki H, Eliot HM, et al. Relationships between proto-oncogene expression and apoptosis induced by anticancer drugs in human prostate tumour cells. Biochem Biophys Acta 1995, 25, 1970 12-18.
16. Huggins C, Hodges CV. The effect of castration, of oestrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941, 1, 942.
17. Byar DP, Corle DK. Hormone therapy for prostate cancer: results of the VACURG studies. In Wittes RE, ed. Consensus development conference on the management of clinically localized prostate cancer. NCI Monograph No. 7, Washington, D.C., Government Printing Office, 1988, 165-170.
18. Parmar H, Phillips RH, Lightman SL, et al. Randomised controlled study of orchidectomy vs long acting D-trp-6-LHRH microcapsules in advanced prostatic carcinoma. Lancet 1985, 2, 1201-1205.
19. Grayhack JT, Keeler TC, Kozlowski JM. Carcinoma of the prostate: hormonal therapy. Cancer 1987, 60(Suppl.), 589-601.
20. Tomic R, Bergman G. Hormonal effects of cessation of oestrogen treatment for prostatic carcinoma. J Urol 1987, 138, 801-803.
21. Schnokowski M, Dousete A, Ekman P, et al. Characterisation and measurement of the androgen receptor in human benign prostatic hyperplasia and prostatic carcinoma. J Clin Endocrinol Metab 1977, 45, 920-930.
22. Hedlund PO, Gustafsson H, Sjogren S. Cardiovascular complications to treatment of prostatic cancer with estramustine phosphate or conventional oestrogen: a follow up of 212 randomised patients. Scand J Urol Nephrol 1980, 55(Suppl.), 103-105.
23. The Leuprolide Study Group. Leuprolide vs diethylstilboestrol for metastatic prostatic cancer. N Engl J Med 1984, 311, 1281-1286.
24. Pavone-Macaluso M, De Voogt HJ, Viggiano G, et al. Comparison of diethylstilboestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer. J Urol 1986, 136, 624-630.
25. Committee on Safety of Medicines. Hepatic reactions with cyproterone acetate. Curr Problems Pharmacovigilance 1995, 21, 1.
26. Sogani PC, Whitmore WF Jr, Experience with flutamide in previously untreated patients with advanced prostatic cancer. J Urol 1979, 122, 640-643.
27. Decensi AU, Boccardo F, Guarneri D, et al. Monotherapy with nilutamide, a pure non-steroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. J Urol 1991, 146, 377-381.
28. Kennealey GT, Furr BJA. Use of the nonsteroidal anti-androgen casodex in advanced prostatic carcinoma. Urol Clin N Am 1991, 18, 99-110.
29. Van den Bossche H, Lauwers W, Willensens G, Cools W. Ketoconazole: an inhibitor of the cytochrome p450 dependent testosterone biosynthesis. Prog Clin Biol Res 1985, 185A, 187-196.
30. Santen RJ, Van den Borssche H, Symoens J, et al. Sites of action of low dose ketoconazole on androgen biosynthesis in men. J Clin Endocrinol Metab 1983, 57, 732-736.
31. Sonimo N. The use of ketoconazole as an inhibitor of steroid production. N Engl J Med 1987, 317, 813-818.
32. Trachtenberg J, Pont A. Ketoconazole therapy for advanced prostate cancer. Lancet 1984, 2, 433-435.
33. Dowsett M, Shearer RJ, Ponder BAJ, Malone P. The effects of aminoglutethemide and hydrocortisone, alone and combined, on androgen levels in post-orchiectomy prostatic cancer patients. Br J Cancer 1988, 57, 190.
34. Robinson MRG. Aminoglutethemide: medical adrenalectomy in the management of carcinoma of the prostate. A review after 6 years. Br J Urol 1980, 52, 328.
35. Davies JH, Dowsett M, Jacobs S, et al. Aromatase inhibition: 4-hydroxyandrostenedione in advanced prostatic cancer. Br J Cancer 1992, 66, 139-142.
36. Plowman PK, Perry LA, Chard T. Androgen suppression by hydrocortisone without aminoglutethimide in orchidectomised men with carcinoma of the prostate. Br J Urol 1987, 59, 225-231.
37. Rittmaster RS, Finastende, N Engl J Med 1994, 330, 120-125.
38. Presti JC Jr, Fair WR, Andriole G, et al. Multicentre, randomised, double-blind, placebo controlled study to investigate the effect of fmasteride (MK-906) on stage D prostate cancer. J Urol 1992, 148, 1201-1204,
39. Myers C, Cooper M, Stern C, et al. Suramin - a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J Clin Oncol 1992, 10, 881-889.
40. Eisenberger MA, Reyno LM, Jodrell DI, et al. Suramin, an active drug for prostate cancer: interim observations in a phase I trial. J Natl Cancer Int 1993, 85, 611-621.
41. Pinski J, Reile H, Halmos G, Groot K, Schally AV. Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer. Cancer Res 1994, 54, 169-174.
42. Bogden AE, Taylor JE, Moreau JP, Coy DH. Treatment of R3327 prostate tumours with a somatostatin analogue (somatulin) as adjuvant therapy following surgical castration. Cancer Res 1990, 50, 2646-2650.
43. Maulard C, Richaud P, Droz JP, et al. Phase I-II study of the somatostatin analogue lanreotide in hormone-refractory prostate cancer. Cancer Chemother Pharmacol 1995, 36, 259-262.
44. Verhelst J, De Longueville M, Ongena P, Denis L, Mahler C. Octreotide in advanced prostatic cancer relapsing under hormonal treatment. Acta Urol Belg 1994, 62, 83-88.
45. Logothetis CJ, Hossan EA, Smith JL. SMS 201-995 in the treatment of refractory prostatic carcinoma. Anticancer Res 1994, 14, 2731-2734.
46. Kockler H, Culig Z, Hobisch A, Cato ACB, Bartsch G. Androgen receptor alterations in prostatic carcinoma. The Prostate 1994, 25, 266-273.
47. Veldscholte J, Ris-Staples C, Kuiper GGJM, et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Comm 1990, 173, 534-540.
48. Scher HI, Kelly WK. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 1993, 11, 1566-1572.
49. Newmark JR, Hardy DO, Tomb DC, et al. Androgen receptor gene mutations in human prostate cancer. Proc Natl Acad Sci USA 1992, 89, 6319-6323.
50. Gaddipati JP, Mcleod DG, Heidenberg HB, et al. Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res 1994, 54, 2861-2864.
51. Culig Z, Hobisch A, Cronaeur MV, et al. Mutant androgen receptor detected in an advanced stage prostatic cancer is activated by adrenal androgens and progesterone. Mol Endocrinol 1993, 7, 1541-1550.
52. Suzuki H, Sato N, Watabe Y, Masai M, Seini S, Shimazaki J. Androgen receptor gene mutation in human prostate cancer. J Steroid Biochem Mol Biol 1993, 46, 759-765.
53. Tilley WD, Buchanan G, Hickey TE, Horsfall DJ. Detection of androgen receptor gene mutations in human prostate cancers by immunohistocytochemistry and PCR-SSCP. Proc 86th Ann Meeting, Am Assoc Cancer Res, Toronto, March 1995, abstract.
54. Taplin ME, Bubley GJ, Shuster TD, et al. Mutation of the androgen receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995, 532, 1393-1398.
55. Tilley WD, Wilson CM, Marcelli M, McPhaul MJ. Androgen receptor gene expression in human prostate cancer cell lines. Cancer Res 1990, 50, 5382-5386.
56. Puizeveld de Winter JA, Janssen PJA, Sleddens HMEB, et al Androgen receptor status in localised and locally progressive hormone-refractory human prostate cancer. Am J Pathol 1994, 144, 735-736.
57. Visakorpi T, Hyytinen E, Kovisto P, et al. Amplification of the androgen receptor gene is common in recurrent prostate cancer from patients treated with androgen withdrawal. Proc Am Urol Assoc, Las Vegas, April 1995, 153(Suppl 4), 379A (abstract).
58. Voeller HJ, Wildding G, Gelmann EP. v-H-ras expression confers hormone independent growth to LNCaP prostate cancer cells. Mol Endocrinol 1991, 5, 209-216,
59. Rubin SJ, Hallahan DE, Ashman CR, et al. Two prostate cancer cell lines demonstrate abnormalities in tumour suppressor genes. J Surg Oncol 1991, 46, 31-36.
60. McDonnell TJ, Troncoso P, Brishay SM, et al. Expression of the proto-oncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992, 52, 6940-6944.
61. Bookstein R, MacGrogen D, Hilsenbeck SG, Sharkey F, Allieo DC. p53 is mutated in a subset of advanced stage prostate cancer. Cancer Res 1993, 53, 3369-3373.
62. Kozlowski JM, Ellis WJ, Grayhack JT. Advanced prostatic carcinoma. Early versus late endocrine therapy. Urol Clin N Am 1991, 18, 15-25.
63. Carter HB, Isaacs JT. Experimental and theoretical basis for hormonal treatment of prostatic cancer. J Urol 1988, 140, 173.
64. Byar DP. The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer 1973, 32, 1126.
65. Byar DP, Coyle D. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group's studies. Natl Cancer Inst Monogr 1988, 7, 165.
66. Va Aubel OG, Hoelistra WJ, Schroder FH. Early orchiectomy for patients with stage D1 prostatic carcinoma. J Urol 1985, 134, 292.
67. Zinder H. Extended experience with surgical treatment of stage D1 adenocarcinoma of the prostate. Significant influences of immediate adjuvant hormonal treatment on outcome. J Urol 1989, 23(Suppl. 5), 27.
68. Labrie F, Vailleux F, Fournier A. Low androgen levels induce the development of androgen hypersensitive cell clones in Shionogi mouse mammary carcinoma cells in culture. J Natl Cancer Inst 1988, 80, 1138-1147.
69. Oesterling JE, Epstein JI, Walsh PC. The viability of adrenal androgens to stimulate the adult human prostate-an autopsy evaluation of men with hypogonadotrophic hypogonadism and panhypopituitarism. J Urol 1986, 136, 1030-1034.
70. Crawford ED, Eisenberger MA, Mcleod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. AT Engl J Med 1989, 321, 419-424.
71. Iverson P, Sucia S, Sylvester R, Christensen I, Denis L. Zoladex and flutamide versus orchidectomy in the treatment of advanced prostatic cancer. Cancer 1990, 66, 1067-1073.
72. Beland G, Elhilali M, Fradet Y, et al. A controlled trial of castration with and without nilutamide in metastatic prostatic carcinoma. Cancer 1990, 66, 1074-1079.
73. Denis LJ, Carneiro de Moura JL, Bono A, et al. Goserelin acetate and flutamide versus bilateral orchidectomy: a phase III EORTC trial. Urology 1993, 42, 119-130.
74. Prostate Cancer Triallists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet 1995, 346, 265-269.
75. Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD, Akakura K. Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology 1995, 45, 839-844.
76. Akakura K, Bruchovsky N, Goldenberg SL, Rennie PS, Buckly AR, Sullivan LD. Effects of intermittent androgen suppression on androgen dependent tumours. Cancer 1993, 71, 2782-2790.
77. Pilepich MV, Sause WT, Shipley WU, et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomised comparative trial of the radiation therapy oncology group. Urology 1995, 45, 616-623.
78. Fair WR, Aprikian A, Sogani P, Reuter V, Whitmore WF. The role of neoadjuvant hormonal manipulation in localised prostatic cancer. Cancer 1993, 71, 1031-1038.